Decay characteristics of HIV-1-infected compartments during combination therapy

Analysis of changes in viral load after initiation of treatment with potent antiretroviral agents has provided substantial insight into the dynamics of human immunodeficiency virus type 1 (HIV-1)1–3. The concentration of HIV-1 in plasma drops by ∼99% in the first two weeks of treatment owing to the rapid elimination of free virus with a half-life (t1/2) of ≤6 hours and loss of productively infected cells with a t1/2 of 1.6 days3. Here we show that with combination therapy this initial decrease is followed by a slower second-phase decay of plasma viraemia. Detailed mathematical analysis shows that the loss of long-lived infected cells (t1/2of1–4 weeks) is a major contributor to the second phase, whereas the activation of latently infected lymphocytes (t1/2 of 0.5–2 weeks) is only a minor source. Based on these decay characteristics, we estimate that 2.3–3.1 years of a completely inhibitory treatment would be required to eliminate HIV-1 from these compartments. To eradicate HIV-1 completely, even longer treatment may be needed because of the possible existence of undetected viral compartments or sanctuary sites.

[1]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[2]  R. Steinman,et al.  Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1 , 1994, Cell.

[3]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[4]  D. Ho,et al.  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1989, The New England journal of medicine.

[5]  G. F. Burton,et al.  Follicular dendritic cells and human immunodeficiency virus infectivity , 1995, Nature.

[6]  Alan S. Perelson,et al.  Quantitative Image Analysis of HIV-1 Infection in Lymphoid Tissue , 1996, Science.

[7]  R. Siliciano,et al.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.

[8]  D. Ho,et al.  Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals , 1993, Journal of virology.

[9]  M A Nowak,et al.  Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. , 1997, Journal of theoretical biology.

[10]  Robert F. Siliciano,et al.  In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency , 1995, Nature Medicine.

[11]  D. Ho,et al.  Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease , 1996, Antimicrobial agents and chemotherapy.

[12]  R Stalnikowicz-Darvasi,et al.  Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events. A critical analysis. , 1995, Journal of clinical gastroenterology.

[13]  H. Gendelman,et al.  Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. , 1986, Science.

[14]  D. Markovitz,et al.  The role of mononuclear phagocytes in HTLV-III/LAV infection. , 1986, Science.

[15]  M A Nowak,et al.  Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Robert Tibshirani,et al.  Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical Accuracy , 1986 .

[17]  A. McLean,et al.  Lifespan of human lymphocyte subsets defined by CD45 isoforms , 1992, Nature.

[18]  M. Vesanen,et al.  Stability in controlling viral replication identifies long-term nonprogressors as a distinct subgroup among human immunodeficiency virus type 1-infected persons , 1996, Journal of virology.

[19]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[20]  M. Hirsch,et al.  Infection of monocyte/macrophages by human T lymphotropic virus type III. , 1986, The Journal of clinical investigation.

[21]  S. Groth,et al.  The evaluation of limiting dilution assays , 1982 .

[22]  D. Dieterich,et al.  Identification and quantitation of HIV‐1 in the liver of patients with AIDS , 1992, AIDS.